This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Mendoza, C.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Mendoza, C.
Right arrow Articles by Soriano, V.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2004, p. 862-866, Vol. 42, No. 2
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.2.862-866.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations

Carmen de Mendoza,1 Ellen Paxinos,2 Pablo Barreiro,1 Nuria Camino,1 Marina Núñez,1 and Vincent Soriano1*

Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain,1 ViroLogic, South San Francisco, California2

Received 29 April 2003/ Returned for modification 11 July 2003/ Accepted 29 October 2003

A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.

* Corresponding author. Mailing address: Service of Infectious Diseases, Hospital Carlos III, Calle Nueva Zelanda 54, 4 B, 28035 Madrid, Spain. Phone: 34 91 453 26 61. Fax: 34 91 733 66 14. E-mail: vsoriano{at}dragonet.es.

Journal of Clinical Microbiology, February 2004, p. 862-866, Vol. 42, No. 2
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.2.862-866.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wainberg, M. A., Brenner, B. G., Turner, D. (2005). Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1671-1678 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»